CORRESP Filing
Ernexa Therapeutics Inc.
Date: June 16, 2025 · CIK: 0000748592 · Accession: 0001641172-25-015240
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287954
Letter
Ernexa Therapeutics Inc.
Cambridge Street, Suite 18A
Cambridge, MA 02141
June 16, 2025
Securities and Exchange Commission
Division of Corporation Finance
F Street N.E.
Washington, D.C. 20549
Re: Ernexa Therapeutics Inc.
Registration Statement on Form S-3
Filed June 11, 2025
File No. 333-287954
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Ernexa Therapeutics Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, June 18, 2025, or as soon as practicable thereafter.
Very truly yours,
Ernexa Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm Ernexa Therapeutics Inc. 1035 Cambridge Street, Suite 18A Cambridge, MA 02141 June 16, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Ernexa Therapeutics Inc. Registration Statement on Form S-3 Filed June 11, 2025 File No. 333-287954 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Ernexa Therapeutics Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, June 18, 2025, or as soon as practicable thereafter. Very truly yours, Ernexa Therapeutics Inc. By: /s/ Sandra Gurrola Sandra Gurrola Senior Vice President, Finance